Last reviewed · How we verify
TTAC-0001 and pembrolizumab combination
TTAC-0001 and pembrolizumab combination is a Small molecule drug developed by PharmAbcine. It is currently in Phase 1 development.
At a glance
| Generic name | TTAC-0001 and pembrolizumab combination |
|---|---|
| Sponsor | PharmAbcine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Olinvacimab With Pembrolizumab in Patients With mTNBC (PHASE2)
- TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma (PHASE1)
- TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TTAC-0001 and pembrolizumab combination CI brief — competitive landscape report
- TTAC-0001 and pembrolizumab combination updates RSS · CI watch RSS
- PharmAbcine portfolio CI
Frequently asked questions about TTAC-0001 and pembrolizumab combination
What is TTAC-0001 and pembrolizumab combination?
TTAC-0001 and pembrolizumab combination is a Small molecule drug developed by PharmAbcine.
Who makes TTAC-0001 and pembrolizumab combination?
TTAC-0001 and pembrolizumab combination is developed by PharmAbcine (see full PharmAbcine pipeline at /company/pharmabcine).
What development phase is TTAC-0001 and pembrolizumab combination in?
TTAC-0001 and pembrolizumab combination is in Phase 1.